Patent 8187811 was granted and assigned to 23andMe on May, 2012 by the United States Patent and Trademark Office.
The invention provides human polymorphisms that are associated with Parkinson's disease (PD). Also disclosed are compositions and methods for use in diagnostics, prognostics, prevention, treatment and/or study of PD.